Expertise in
8
conditions

Dana Ranta

Nancy, FR 
Expertise in
8
conditions
Nancy, FR 

Overview

Dana Ranta practices practicing medicine in Nancy, France.

Ranta is highly rated in 8 conditions, according to our data. Their clinical expertise encompasses Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Myelofibrosis, and Essential Thrombocythemia.

They are actively involved in clinical research, co-authoring 31 peer reviewed articles and participating in 2 clinical trials.

Locations

Nancy, France
Other Locations
Lens, France
Paris, France
Vandoeuvre-les-nancy, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2026
Intervention Type: Drug
Study Drugs: CPI-0610 BET Small Molecule Inhibitor, Ruxolitinib
Study Phase: Phase 3
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Lenalidomide and GA101
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

31 Total Publications

Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.
Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.
Journal: The Lancet. Haematology
Published: January 30, 2026

Frequently Asked Questions about Dana Ranta

Is Dana Ranta a top-rated expert for Polycythemia Vera?

MediFind is an objective health platform that identifies experts based on real-world data. Dana Ranta is classified as an Distinguished expert for Polycythemia Vera, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Dana Ranta participate in research or clinical trials?

Yes. Dana Ranta has published 31 articles and abstracts on conditions like Polycythemia Vera. You can view a list of Dana Ranta's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ranta's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile